You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 21, 2025

Details for Patent: 3,980,778


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 3,980,778
Title: Anti-inflammatory steroid
Abstract:The disclosure covers the preparation of the compound, 6.alpha.,9.alpha.-difluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna -1,4-diene-3,20-dione 17.alpha.,21-diacetate, (1) and methods and formulations for its anti-inflammatory use topically, orally and parenterally.
Inventor(s): Ayer; Donald E. (Kalamazoo, MI), Schlagel; Carl A. (Kalamazoo, MI), Flynn; Gordon L. (Ann Arbor, MI)
Assignee: The Upjohn Company (Kalamazoo, MI)
Application Number:05/579,177
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of U.S. Patents: A Detailed Analysis

Introduction

When navigating the complex landscape of U.S. patents, it is crucial to understand the scope and claims of a patent to ensure compliance, innovation, and protection of intellectual property. This article will delve into the key aspects of patent scope, claims, and the recent updates in the patent landscape, particularly focusing on the principles that can be applied to any U.S. patent, including the hypothetical example of U.S. Patent 3,980,778.

What are Patent Claims?

Patent claims are the heart of a patent application, defining the scope of the invention for which protection is sought. They are the legal boundaries that distinguish the invention from prior art and other existing technologies[3].

Types of Patent Claims

Independent Claims

Independent claims stand alone and do not refer to any other claims in the patent. They define the broadest scope of the invention and are critical in determining the patent's overall scope[5].

Dependent Claims

Dependent claims refer back to an independent claim or another dependent claim, narrowing down the scope of the invention. These claims are used to provide additional details and specific embodiments of the invention.

Measuring Patent Scope

Patent scope can be measured using various metrics, including independent claim length and independent claim count. These metrics help in assessing the breadth and clarity of the patent claims. For instance, narrower claims at publication are associated with a higher probability of grant and a shorter examination process[5].

Recent Updates in Patent Eligibility: The 2024 USPTO Guidance

The 2024 USPTO guidance update, prompted by Executive Order 14110, has significant implications for AI-related inventions and general patent eligibility.

Evaluating Practical Applications

The update emphasizes the importance of evaluating whether a claim integrates a judicial exception into a practical application. This involves assessing additional elements in the claim to determine if they impose meaningful limits on the exception, transforming the claim into patent-eligible subject matter[1].

AI-Assisted Inventions

The guidance clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies[1].

Incorporation of Recent Case Law

The update integrates recent Federal Circuit decisions, providing up-to-date legal standards and interpretations. This helps in promoting consistency and clarity in the application of patent eligibility criteria, reflecting the latest judicial thinking[1].

Practical Applications and Patent Eligibility

Example from the 2024 USPTO Guidance

For instance, Example 48 from the 2024 USPTO guidance illustrates how specifying the use of separated audio components in a real-time speech recognition system can transform an abstract idea into a patent-eligible invention. This practical application adds a meaningful limit and integrates the judicial exception into a concrete technological improvement[1].

Case Law and Patent Validity

Allergan USA, Inc. v. MSN Laboratories Private Ltd.

Recent case law, such as Allergan USA, Inc. v. MSN Laboratories Private Ltd., highlights the importance of written description and obviousness-type double patenting in determining patent validity. This case underscores the need for clear and distinct claims that avoid overlapping with prior patents[2].

Data-Driven Insights: The Patent Claims Research Dataset

The Patent Claims Research Dataset provided by the USPTO offers detailed information on claims from U.S. patents granted between 1976 and 2014 and patent applications published between 2001 and 2014. This dataset helps in analyzing claim language, dependency relationships, and the trends in patent scope measurements[3].

Key Takeaways for Patent Scope and Claims

  • Clear and Specific Claims: Ensure that patent claims are clear, specific, and integrate judicial exceptions into practical applications to avoid section 101 rejections.
  • Practical Applications: Highlighting real-world applications of the claimed method or system is crucial for demonstrating patent eligibility.
  • AI-Assisted Inventions: The use of AI in invention development does not affect subject matter eligibility, provided there is significant human contribution.
  • Recent Case Law: Stay updated with recent Federal Circuit decisions to ensure consistency and clarity in patent eligibility criteria.
  • Data-Driven Analysis: Utilize datasets like the Patent Claims Research Dataset to analyze and optimize patent claims.

FAQs

What is the significance of the 2024 USPTO guidance update on AI patent eligibility?

The 2024 USPTO guidance update refines and clarifies the process for determining the patent eligibility of AI-related inventions, providing examples and detailed eligibility analysis to help practitioners evaluate and draft patent claims more effectively[1].

How do practical applications impact patent eligibility?

Practical applications are crucial in transforming abstract ideas into patent-eligible inventions. By specifying the use of the claimed method or system in a real-world application, inventors can demonstrate concrete technological improvements and meet the criteria for patent eligibility[1].

What role does AI play in patent eligibility?

The method of invention development, including the use of AI, does not impact subject matter eligibility. The focus remains on the claimed invention itself, ensuring AI-assisted inventions are evaluated on equal footing with other technologies[1].

How can the Patent Claims Research Dataset be useful?

The dataset provides detailed information on claims from U.S. patents and applications, helping in analyzing claim language, dependency relationships, and trends in patent scope measurements. This can aid in optimizing patent claims and understanding broader patent landscape trends[3].

What are the key metrics for measuring patent scope?

Key metrics include independent claim length and independent claim count. These metrics help in assessing the breadth and clarity of the patent claims and have explanatory power for several correlates of patent scope[5].

Key Takeaways

  • Clear Claims: Ensure patent claims are clear and specific.
  • Practical Applications: Highlight real-world applications to demonstrate patent eligibility.
  • AI Integration: AI-assisted inventions are evaluated based on the claimed invention, not the method of development.
  • Case Law: Stay updated with recent judicial decisions.
  • Data Analysis: Use datasets to optimize and analyze patent claims.

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. ALLERGAN USA, INC. v. MSN LABORATORIES PRIVATE LTD. - CAFC
  3. Patent Claims Research Dataset - USPTO
  4. Topical clindamycin preparations - Patent US-4018918-A - PubChem
  5. Patent Claims and Patent Scope - SSRN

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 3,980,778

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
No data available in table
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 0 to 0 of 0 entries

International Family Members for US Patent 3,980,778

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Argentina 197216 ⤷  Try for Free
Australia 468257 ⤷  Try for Free
Australia 5257973 ⤷  Try for Free
Belgium 796560 ⤷  Try for Free
Belgium 821496 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 5 of 5 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.